IL-6 Blockade With Clazakizumab Is Associated With Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Nonsurvivors of COVID-19
The Journal of Infectious Diseases · 27.10.2026
DOI: 10.1093/infdis/jiag510 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 27.10.2026. Verfasst von Laila Stoddart und 9 weiteren Autor:innen. Beteiligte Einrichtung: W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 212…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Background
IL-6 inhibitors have been associated with reduced mortality in severe COVID-19 in randomized clinical trials, but the comprehensive immunological impact of IL-6 blockade in the setting of an acute viral infection is poorly understood.
Methods
To gain insight into the systemic immune response to IL-6 inhibition in COVID-19, we utilized samples from patients who participated in a randomized, placebo-controlled trial of clazakizumab, a direct anti-IL-6 monoclonal antibody, in severe COVID-19 in the prevaccine era. We applied multidimensional measurements of cytokines, chemokines, whole-blood transcriptomes, and high-dimensional immunometabolic flow cytometry to samples before and after treatment to study the changes in immune signatures after IL-6 blockade and to identify pathways associated with positive clinical outcomes.
Results
Clazakizumab was associated with a distinct myeloid activation signature and type 2 (T2) cytokine response. Nonsurvivors who received clazakizumab demonstrated a decoupling of these 2 clazakizumab-associated phenotypes, exhibiting the most pronounced T2 response coupled with less myeloid activation. Furthermore, elevated baseline levels of the emergency myelopoiesis-related cytokine, IL-27, were strongly associated with nonsurvival after receipt of clazakizumab.
Conclusions
These findings suggest that specific biomarkers may identify patients most likely to benefit from IL-6 blockade and could lead to more personalized applications in COVID-19 and other inflammatory conditions in which IL-6 targeted therapies are in use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
- Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
ORCID-Profile: Laila Stoddart, Trevor S Johnston, Sherry Leung, Elizabeth A Thompson, Andrea L Cox, Andrew H Karaba
Förderung
- National Institutes of Health
Zitieren
APA
Stoddart, L., Johnston, T. S., Zhou, W., El-Diwany, R., Leung, S., Alachkar, N., Wesson, R. N., Thompson, E. A., Cox, A. L., & Karaba, A. H. (2026). IL-6 Blockade With Clazakizumab Is Associated With Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Nonsurvivors of COVID-19. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag510
Vancouver
Stoddart L, Johnston TS, Zhou W, El-Diwany R, Leung S, Alachkar N, et al. IL-6 Blockade With Clazakizumab Is Associated With Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Nonsurvivors of COVID-19. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag510
BibTeX
@article{Stoddart2026,
author = {Stoddart, Laila and Johnston, Trevor S and Zhou, Weiqiang and El-Diwany, Ramy and Leung, Sherry and Alachkar, Nada and Wesson, Russell N and Thompson, Elizabeth A and Cox, Andrea L and Karaba, Andrew H},
title = {IL-6 Blockade With Clazakizumab Is Associated With Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Nonsurvivors of COVID-19},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag510}
}
EUVIMED